Brind.

Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.

Steady: 0 in the last 7 days Updated sep 17

The latest in this situation

  1. Novartis acquires Sironax's brain delivery platform, which also gained FDA fast track status.
  2. Novartis completes the acquisition of Avidity Biosciences, but the acquired technology platform failed a key clinical trial.
  3. Novartis drug failure increases CEO pressure as the company completes the acquisition of Avidity.

How it started

10 reports, 3 independent, last reported Sep 16. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.

Who's involved

What this event is mainly about
NovartisRegulus TherapeuticsAvidity

How it developed

Newest first. Tap a step to see who reported it.
  1. Novartis acquires Sironax's brain delivery platform, which also gained FDA fast track status.1 source
  2. Novartis drug failure increases CEO pressure as the company completes the acquisition of Avidity.1 source
  3. Novartis completes the acquisition of Avidity Biosciences, but the acquired technology platform failed a key clinical trial.1 source
  4. Novartis made a tender offer to acquire Regulus Therapeutics, filing the necessary documents with the SEC on June 25, 2025.Sub-event
  5. Novartis completes acquisition of Regulus Therapeutics and considers Avidity Biosciences.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • biopharmadive.com
  • theglobeandmail.com
  • biopharmadive.com
  • ReutersNovartis weighs deal for biotech Avidity Biosciences, FT reports (Reuters) -Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Time
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet
3 more outlets ran the same wire story